Heterogeneity of Oral Carcinogenesis: From PrEneoplasia to Invasive Squamous Cell Carcinoma
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorCentre Leon Berard
About this trial
The goal of this project is to characterise the heterogeneity of all cell populations (tumour cells, stromal and immune microenvironment) present in the tumor and their normal (and OPMD) counterparts by scRNAseq in OSCC patients. Additionally, the study will evaluate the effectiveness of non-invasive cytobrushes as a diagnostic tool compared to traditional biopsies.
Eligibility criteria
Qualifiers
I1: Male or female at least 18 years old.
I2: For Cohort A: patients with OSCC who undergo surgery. For cohorts B and C: patients with OPMD.
I3: Patient who has agreed to participate in this research and sign consent.
I4: Patient affiliated to a medical insurance.
Disqualifiers
NI1: For cohorts B and C: Patient at high risk of bleeding, such as those receiving anticoagulant or antiplatelet therapy, those with coagulation disorders, or those with a history of severe bleeding within the two weeks prior to enrollment.
NI2: Pregnant or nursing woman.
NI3: Contraindication to general anesthesia.
NI4: Suspicion of rare tumor of particular histology other than squamous cell carcinoma (Sarcoma...).
Trial design
Treatments tested in this trial
- Biospecimen
- Blood sampling
- Biospecimen
- Biospecimen
Treatment groups
150 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov